A Phase I Study of the Safety and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Trial Profile

A Phase I Study of the Safety and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs GEN 1 (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms OVATION
  • Sponsors Celsion Corporation
  • Most Recent Events

    • 03 Oct 2017 According to a Celsion Corporation media release, final clinical and translational research data from the study has been presented at the American Association of Cancer Research (AACR) Special Conference 2017.
    • 03 Oct 2017 Clinical and translational research data from the study published in Celsion Corporation media release.
    • 24 Aug 2017 Results published in a Celsion Corporation Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top